FAS and melanoma: FAS levels in melanoma LM16 R cells were found to negatively correlate with IC50 values of Vemurafenib (an approved BRAF inhibitor), and the silence of FAS could enhance the cytotoxicity of PLX4032 to PLX4032-resistant LM16 R cells (Stamatakos et al., 2021).